Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Price Helps Secure Funding For Rubraca In England

Clovis's PARP Inhibitor Will Be Available Through The Cancer Drugs Fund

Executive Summary

Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.

You may also be interested in...



New Keytruda Combo Wins Funding In England For NSCLC

MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.

NICE Yes For Lynparza In England May Have 'Huge Impact' For Ovarian Cancer

AstraZeneca and MSD's Lynparza can now be paid for through England’s Cancer Drugs Fund for use in women with advanced BRCA-mutated ovarian cancer when their disease is newly diagnosed and when the drug may have the potential to cure their disease.

UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs

Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.

Topics

UsernamePublicRestriction

Register

PS140988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel